Medical/Pharmaceuticals

Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment with sparsentan resulted in a reduction of proteinuria that was sustained through 108 weeks of treatment S...

2023-05-03 00:22 3347

iHerb Names Miriee Chang as Chief Operating Officer

Newly established role will further streamline operations and enhance operational effectiveness IRVINE, Calif., May 3, 2023 /PRNewswire/ -- iHerb Holdings, LLC, announced that Miriee Chang has been named its Chief Operating Officer (COO). Mrs. Chang brings significant leadership experience to th...

2023-05-03 00:14 2980

Cellenkos Announces First Patient Dosed with CK0803 Cell Therapy for Treatment of Amyotrophic Lateral Sclerosis

* First patient dosed with CK0803 Treg cells for treatment of amyotrophic lateral sclerosis (ALS). * Ongoing Phase 1/1b study evaluating safety and efficacy of CK0803. HOUSTON, May 3, 2023 /PRNewswire/ -- Cellenkos® Inc., a clinical stage biotechnology company focused on developing allogeneic...

2023-05-03 00:07 2025

Ascletis Announces ASC40, a First-in-Class, Once-Daily Oral FASN Inhibitor, Achieved Endpoints in Phase II Clinical Trial for Acne

HANGZHOU and SHAOXING, China, May 2, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that ASC40 (Denifanstat), a first-in-class, once-daily oral fatty acid synthase (FASN) inhibitor, achieved primary and key secondary endpoints in Phase II clinical trial for acn...

2023-05-02 17:30 3560

Cytiva and Pall Life Sciences complete integration to create a global innovation and solutions leader in biotechnology

* Combined broad and differentiated portfolio with trusted technologies and commercial and service organizations * Customers will have simpler and greater access to industry-leading expertise, tools, and services AMERSHAM, United Kingdom, May 2, 2023 /PRNewswire/ -- Cytiva and the life scienc...

2023-05-02 12:01 3539

First Patients in Canada Imaged with Illuccix®: Now Commercially Available Nationwide

MELBOURNE, Australia, May 2, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces first patients have been imaged inCanada with its commercially available prostate cancer imaging agent, Illuccix® [kit for the preparation of gallium (68Ga) PSMA-11 for i...

2023-05-02 05:00 2294

Concept Medical received IDE approval to investigate safety and efficacy of its MagicTouch Sirolimus Coated Balloon Catheter for the treatment of small coronary artery disease

TAMPA, Fla., May 1, 2023 /PRNewswire/ -- The US FDA has granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc's novel MagicTouch Sirolimus Coated Balloon (SCB) for the treatment of Small Vessels (SV) in coronary ar...

2023-05-01 18:30 2855

Zimmer Biomet Announces Acquisition of OSSIS

SINGAPORE, May 1, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced it has reached a definitive agreement to acquire OSSIS, a privately-held medical device company that specializes in personalized 3D printed implants, as wel...

2023-05-01 12:00 5250

GILEAD SCIENCES ANNOUNCES LAUNCH OF ASIA PACIFIC RAINBOW GRANT 2023

–Gilead Sciences Celebrates the Fifth Anniversary Milestone of the Asia Pacific Rainbow Grant, with More Than US$4.5 Million Awarded to Organizations across the Asia Pacific Region to Date – – Grant Program in 2023 Invites HIV-Focused Community-Based Organizations to Apply for Funding for Innova...

2023-05-01 11:00 3231

ZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller

MELBOURNE, Australia, May 1, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89 Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalT...

2023-05-01 08:58 2701

European Wellness Collaborates with Heidelberg University in Journal Publications of "Synergistic Anti-Ageing Through Senescent Cells Specific Reprogramming"

HEIDELBERG, Germany, April 28, 2023 /PRNewswire/ -- European Wellness Academy (EWA), an educational arm of European Wellness Biomedical Group (EW Group), has collaborated with Heidelberg University on journal publication. The research project, titled "Synergistic Anti-Ageing Through Senescent Cel...

2023-04-28 11:58 2785

HOYA Vision Care Elevates Children's Protection Against Myopia & Intensive Light With MiYOSMART Sun Lenses

SINGAPORE, April 28, 2023 /PRNewswire/ -- HOYA Vision Care , a leader in optical technology innovation, has launched MiYOSMART Sun spectacle lenses inSingapore, which are designed to be effective and non-invasive protection against myopia for children. The photochrom...

2023-04-28 11:18 2774

Brii Bio Publishes 2022 Environmental, Social and Governance Report

Brii Bio receives an "A" grade in the latest MSCI ESG Rating DURHAM, N.C. and BEIJING, April 28, 2023 /PRNewswire/ -- Brii Biosciences Limited  ("Brii Bio" or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health ...

2023-04-28 09:00 3004

OrthAlign's 50th Patent Affirms Position as A Global Leader in Surgical Navigation

ALISO VIEJO, Calif., April 28, 2023 /PRNewswire/ -- OrthAlign® Inc., a global leader in orthopedic surgical navigation technology, continues to expand its IP portfolio, with its 50th patent being issued. OrthAlign pioneered and continues to enhance surgical navigation solutions proven to enable a...

2023-04-28 04:33 2341

RNAimmune Receives FDA Clearance of Investigational New Drug Application for Phase 1 Trial of RV-1730 COVID-19 Booster Vaccine

GERMANTOWN, Md. and GUANGZHOU, China, April 28, 2023 /PRNewswire/ -- RNAimmune, Inc.(the "Company" or "RNAimmune"), a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, today announced that the Company has received a clearance from the Uni...

2023-04-28 00:29 3111

Steakholder Foods® 3D Bio-Prints First Ready-to-Cook Cultivated Grouper Fish

Steakholder Foods 3D bio-printed the world's first cultivated fish fillet: * The Company has reached a significant milestone by successfully customizing bio-inks utilizing grouper cells provided by Umami Meats' to print a cultivated grouper product – a significant step towards the commercializa...

2023-04-27 23:50 4768

Fapon Biotech Announces Chemiluminescence One-Stop Solution Strategy in India at Medical Fair India 2023

NEW DELHI, April 27, 2023 /PRNewswire/ -- Fapon Biotech Inc. (Fapon Biotech, or the Company), a global leading IVD enterprise, has announced its innovative chemiluminescence one-stop solution strategy at the 28th edition of Medical Fair India. Fapon chemiluminescence one-stop solution is designe...

2023-04-27 18:44 2147

Qiming Venture Partners' portfolio company MedSci successfully listed on HKEX main board

SHANGHAI, April 27, 2023 /PRNewswire/ -- On April 27th Beijing time, Qiming Venture Partners' portfolio company MedSci Healthcare Holdings Limited ("MedSci"), a leading physician digital platform inChina, successfully listed on the main board of Hong Kong Stock Exchange. MedSci (02415.HK)'s issue...

2023-04-27 15:53 3352

Bactiguard Holding AB's report for the first quarter 2023

Continued focus on growth and transformation STOCKHOLM, April 27, 2023 /PRNewswire/ --  First quarter 2023, January-March * Revenues amounted to SEK 61.2 (55.2) million, an increase of 11%. Adjusted for currency effects, revenues decreased by 4%. * Operating loss amounted to SEK 18.7 (16.6) ...

2023-04-27 14:47 1921

BioCina awarded Grants to develop enabling technologies for manufacture of precision mRNA vaccines

MIAMI and ADELAIDE, Australia, April 27, 2023 /PRNewswire/ -- BioCina, a leading contract development and manufacturing organization (CDMO) is pleased to announce that it has been awarded a$5.0m AUD grant under the Federal Government's Medical Research Future Fund (MRFF) Grants scheme to fund wor...

2023-04-27 12:15 2298
1 ... 113114115116117118119 ... 397

Week's Top Stories